Bristol-myers Squibb Compnay

Chongqing Sun

William R Ewing

Yanting Huang

Annapurna Pendri

Natesan Murugesan

Bruce A Ellsworth

Samuel Gerritz

Doree F Sitkoff

Philip Michael Sher

Richard B Sulsky

Yeheng Zhu

Zhengxiang Gu

Lawrence G Hamann

Mark E Salvati

Taekyu Lee

Tammy C Wang

Guixue Yu

Gang Wu

Amarendra B Mikkilineni

Jeffrey A Robl

David John Augeri

Maheswaran Sivasamban Karatholuvhu

Ximao Wu

Scott A Bolton

Ying Wang

R Michael Lawrence

James Aaron Balog

Dharmpal S Dodd

James Clifford Sutton

Ricardo Attar

Marco Gottardis

Laxman Pasunoori

Jun Shi

Xiang-Yang Ye

Alexandra A Nirschl

Elizabeth Anne Jurica

Huji Turdi

Dacia A Pickering

Yan Zou

Sunil Kumar Mandal

Rogelio L Martinez

Stephen R Johnson

The present invention provides compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments. 

Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH, or CH; Z is CH or N; Rand Rare hydrogen or (C-C)alkyl; Ris (C-C)alkoxy, OH, CN, (C-C)alkyl, halogen, or CF; r and s are 0, 1, or 2; and Rand Rare as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor. 

Substituted adipic acid amides and uses thereof

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.

Diaminocyclohexane compounds and uses thereof

Disclosed are triazolopyridine compounds of the following Formula (I); or stereoisomers or salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof. 

Triazolopyridine compounds useful as DGAT1 inhibitors

Disclosed are triazolopyridine compounds of Formula (I), including pharmaceutically acceptable salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof. 

Triazolo compounds useful as DGAT1 inhibitors

The invention provides for compounds of formula I  Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

Tetrahydroquinoline derivatives as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R, R, Rand Rare described herein.

Bicyclic heterocycles as cannabinoid-1 receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, n, and Z are described herein.

Tetrahydroquinoline cannabinoid receptor modulators

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R, R, R, X, Y and n are defined herein.

Bicyclic modulators of androgen receptor function

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R, R, R, Rand Rare described herein.

Triazolopyridine cannabinoid receptor 1 antagonists

Growing community of inventors

East Windsor, NJ, United States of America

Chongqing Sun